Showing 4,161 - 4,180 results of 60,547 for search '(( 5 ((we decrease) OR (teer decrease)) ) OR ( 50 ((a decrease) OR (mean decrease)) ))', query time: 0.77s Refine Results
  1. 4161

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  2. 4162

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  3. 4163

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  4. 4164

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  5. 4165

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  6. 4166
  7. 4167

    Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter by Zhi-Zheng Wang (6056033)

    Published 2023
    “…Here, we proposed the concept of “nonbioavailable substructures”, referring to substructures that are unfavorable to bioavailability. …”
  8. 4168

    Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter by Zhi-Zheng Wang (6056033)

    Published 2023
    “…Here, we proposed the concept of “nonbioavailable substructures”, referring to substructures that are unfavorable to bioavailability. …”
  9. 4169

    Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter by Zhi-Zheng Wang (6056033)

    Published 2023
    “…Here, we proposed the concept of “nonbioavailable substructures”, referring to substructures that are unfavorable to bioavailability. …”
  10. 4170

    Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter by Zhi-Zheng Wang (6056033)

    Published 2023
    “…Here, we proposed the concept of “nonbioavailable substructures”, referring to substructures that are unfavorable to bioavailability. …”
  11. 4171

    Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter by Zhi-Zheng Wang (6056033)

    Published 2023
    “…Here, we proposed the concept of “nonbioavailable substructures”, referring to substructures that are unfavorable to bioavailability. …”
  12. 4172
  13. 4173

    NbVO<sub>5</sub> Mesoporous Thin Films by Evaporation Induced Micelles Packing: Pore Size Dependence of the Mechanical Stability upon Thermal Treatment and Li Insertion/Extraction by Natacha Krins (2066203)

    Published 2011
    “…In order to investigate the potentialities and limits of the soft-templating approach in the case of complex transition metal oxide networks, we deliberately selected a “difficult” compound: NbVO<sub>5</sub> was chosen because it combines a challenging synthesis with reported severe structural distortions during the first lithium insertion in the bulk material. …”
  14. 4174
  15. 4175

    Concentrations of 5-HT and 5-HIAA in brain tissue. by Thibault Renoir (348572)

    Published 2013
    “…<p>Using the HPLC system, we measured the tissue levels of serotonin (5-HT) and its metabolite 5-hydroxyindolacetic acid (5-HIAA) in several brain areas. …”
  16. 4176

    Loss of epithelial markers is an early event in oral dysplasia and is observed within the safety margin of dysplastic and T1 OSCC biopsies by Zahra Abdalla (4669927)

    Published 2017
    “…Here we have assessed expression of the oral epithelial markers E-cadherin, EMP1 and 5T4 and the pro-invasive N-cadherin proteins using fully characterised antibodies and quantitative immunofluorescence microscopy in normal tissue (NT), fibroepithelial polyp (FEP), low-grade dysplasia (LGD), high-grade dysplasia (HGD), T1 OSCC and T4 OSCC biopsies. …”
  17. 4177
  18. 4178
  19. 4179
  20. 4180

    Supplementary Material for: 3,4-Methylenedioxymethamphetamine (Ecstasy) Decreases Inflammation and Airway Reactivity in a Murine Model of Asthma by Stankevicius D. (4130146)

    Published 2012
    “…We also showed that MDMA decreased expression of both Th2-like cytokines (IL-4, IL-5 and IL-10) and adhesion molecules (L-selectin). …”